Invention Grant
- Patent Title: 18/19F-labelled compounds which target the prostate specific membrane antigen
-
Application No.: US16068992Application Date: 2017-01-10
-
Publication No.: US10882871B2Publication Date: 2021-01-05
- Inventor: Francois Benard , Kuo-shyan Lin , David Perrin , Zhibo Liu , Hsiou-ting Kuo , Jinhe Pan , Aron Roxin , Mathieu Lepage
- Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCH , THE UNIVERSITY OF BRITISH COLUMBIA
- Applicant Address: CA Vancouver; CA Vancouver
- Assignee: BRITISH COLUMBIA CANCER AGENCY BRANCH,THE UNIVERSITY OF BRITISH COLUMBIA
- Current Assignee: BRITISH COLUMBIA CANCER AGENCY BRANCH,THE UNIVERSITY OF BRITISH COLUMBIA
- Current Assignee Address: CA Vancouver; CA Vancouver
- Agency: Sheridan Ross P.C.
- International Application: PCT/CA2017/050026 WO 20170110
- International Announcement: WO2017/117687 WO 20170713
- Main IPC: A61K51/00
- IPC: A61K51/00 ; A61M36/14 ; C07F5/02 ; A61K51/04 ; C07F5/00 ; A61P35/00 ; C07B59/00
Abstract:
This disclosure relates to novel compounds comprising a zwitterionic trifluoroborate prosthetic group which target prostate-specific membrane antigen (PSMA), e.g. in prostate cancer. The compounds have Formula I, wherein each R1 is an anionic group, L is a linker and R2B-F3 is —N(R3)2CH2BF3, a pyridinium group substituted with BF3 or methyl BF3, or an azole group substituted with methyl BF3. Methods and uses of imaging and treating PSMA-expressing cancers are also disclosed.
Public/Granted literature
- US20190010171A1 18/19F-LABELLED COMPOUNDS WHICH TARGET THE PROSTATE SPECIFIC MEMBRANE ANTIGEN Public/Granted day:2019-01-10
Information query
